Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, Univ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dillon PM, Brenin CM, Slingluff CL Jr
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	vaccine breast cancer her2 peptide human Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8f13b704edc548b7967b873fe2665815
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f13b704edc548b7967b873fe2665815
record_format	dspace
spelling	oai:doaj.org-article:8f13b704edc548b7967b873fe26658152021-12-02T09:39:32ZEvaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data1179-1314https://doaj.org/article/8f13b704edc548b7967b873fe26658152020-04-01T00:00:00Zhttps://www.dovepress.com/evaluating-nelipepimut-s-in-the-treatment-of-breast-cancer-a-short-rep-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, University of Virginia, Box 800716, Charlottesville, VA 22908, USATel +1-434-982-1495Fax +1-434-244-7534Email Pmd5b@hscmail.mcc.virginia.eduAbstract: Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.Keywords: vaccine, breast cancer, HER2, peptide, humanDillon PMBrenin CMSlingluff CL JrDove Medical Pressarticlevaccinebreast cancerher2peptidehumanNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 12, Pp 69-75 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	vaccine breast cancer her2 peptide human Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	vaccine breast cancer her2 peptide human Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Dillon PM Brenin CM Slingluff CL Jr Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
description	Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, University of Virginia, Box 800716, Charlottesville, VA 22908, USATel +1-434-982-1495Fax +1-434-244-7534Email Pmd5b@hscmail.mcc.virginia.eduAbstract: Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.Keywords: vaccine, breast cancer, HER2, peptide, human
format	article
author	Dillon PM Brenin CM Slingluff CL Jr
author_facet	Dillon PM Brenin CM Slingluff CL Jr
author_sort	Dillon PM
title	Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
title_short	Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
title_full	Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
title_fullStr	Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
title_full_unstemmed	Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
title_sort	evaluating nelipepimut-s in the treatment of breast cancer: a short report on the emerging data
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8f13b704edc548b7967b873fe2665815
work_keys_str_mv	AT dillonpm evaluatingnelipepimutsinthetreatmentofbreastcancerashortreportontheemergingdata AT brenincm evaluatingnelipepimutsinthetreatmentofbreastcancerashortreportontheemergingdata AT slingluffcljr evaluatingnelipepimutsinthetreatmentofbreastcancerashortreportontheemergingdata
_version_	1718398076561915904

Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

Ejemplares similares